
Latest Updates
Vycor
Vycor (OTCQB: VYCO), headquartered in Boca Raton, Florida, is dedicated to developing innovative, minimally invasive solutions. Vycor's VBAS system has been approved and used in over 300 US facilities and numerous countries internationally. VBAS is protected by 46 issued and 11 pending patents and has been validated through over 40 studies. Vycor's NoraVision is a unique and important option for those seeking to regain lost visual capabilities. Together, Vycor and NovaVision are addressing critical unmet needs, improving outcomes, and offering life-changing solutions to individuals.
Stock Details
Recent News
SEC Filings
Vycor Medical is focused on advancing neurosurgical and vision rehabilitation technologies. The company’s ViewSite™ Brain Access System (VBAS) is a minimally-invasive neurosurgical device designed to reduce tissue damage and improve surgical access and patient outcomes for complex brain procedures. Vycor’s NovaVision® platform provides a suite of clinically supported vision rehabilitation therapies for stroke and brain injury patients.
With FDA-cleared or registered technologies, a substantial and growing body of clinical validation, and an established presence in hospitals across the U.S. and internationally, Vycor Medical is positioned to address critical unmet needs in neurosurgery and neuro-rehabilitation.
Vycor Medical is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance.
See official press release at https://www.newmediawire.com/news/vycor-medical-joins-b2i-digital-venture-company-program-to-build-and-educate-its-investor-base-7079868.
Learn more about Vycor Medical at tps://www.vycormedical.com/investment-highlights. For investor inquiries, please contact info@vycormedical.com.
#VycorMedical #Neurosurgery #VisionRestoration #B2iDigital
@B2iDigital DavidShapiro

Vycor Medical is focused on advancing neurosurgical and vision rehabilitation technologies. The company’s ViewSite™ Brain Access System (VBAS) is a minimally-invasive neurosurgical device designed to reduce tissue damage and improve surgical access and patient outcomes for complex brain procedures. Vycor’s NovaVision® platform provides a suite of clinically supported vision rehabilitation therapies for stroke and brain injury patients.
With FDA-cleared or registered technologies, a substantial and growing body of clinical validation, and an established presence in hospitals across the U.S. and internationally, Vycor Medical is



Vycor Medical is focused on advancing neurosurgical and vision rehabilitation technologies. The company’s ViewSite™ Brain Access System (VBAS) is a minimally-invasive neurosurgical device designed to reduce tissue damage and improve surgical access and patient outcomes for complex brain procedures. Vycor’s NovaVision® platform provides a suite of clinically supported vision rehabilitation therapies for stroke and brain injury patients.
With FDA-cleared or registered technologies, a substantial and growing body of clinical validation, and an established presence in hospitals across the U.S. and internationally, Vycor Medical is positioned to address critical unmet needs in neurosurgery and neuro-rehabilitation.
Vycor Medical is led by CEO Peter Zachariou, President David Cantor, and CFO Adrian Liddell, each bringing extensive experience in medical technology, business development, and finance.
See official press release at https://www.newmediawire.com/news/vycor-medical-joins-b2i-digital-venture-company-program-to-build-and-educate-its-investor-base-7079868.
Learn more about Vycor Medical at tps://www.vycormedical.com/investment-highlights. For investor inquiries, please contact info@vycormedical.com.
#VycorMedical #Neurosurgery #VisionRestoration #B2iDigital
@B2iDigital @DavidShapiro

Management Team
PETER ZACHARIOU
PETER ZACHARIOU
Chief Executive Officer
Mr. Zachariou was appointed a Director of the Company in May 2010, Executive Vice President in September 2010 and Chief Executive Officer on January 2, 2014. As CEO, he has responsibility for the sales, marketing and customer functions of both the Vycor and NovaVision divisions. For the past 30 years, Mr. Zachariou has been an active investor in and proprietor of a variety of companies and industries, predominantly in U.S. emerging and growth companies across a broad range of industry sectors. He is an investment manager for Fountainhead Capital Management Limited, an investment company based in Jersey, Channel Islands.

DAVID CANTOR
DAVID CANTOR
President and Director
David Cantor has been President of the Company since September 2010 and a Director since January 2010. As President, he has responsibility for the clinical, program and product development and manufacturing functions of both the Vycor and NovaVision divisions, as well as their patent and trademark portfolios. Mr. Cantor has over 22 years of experience in Investment Banking with a focus on Mergers and Acquisitions and Equity Capital Raisings. From 2001 – 2005, he was at Citigroup Capital Markets, where he was Co-head of its M&A European Business Development Group and subsequently European Head of its Diversified Industrials and Aerospace activities. Prior to Citigroup he was a Managing Director in M&A at Donaldson Lufkin & Jenrette and worked at Lehman Brothers both in New York and London in both the Equity Capital and M&A groups. He is an investment manager of Fountainhead Capital Management Limited, an investment company based in Jersey, Channel Islands. Mr. Cantor has a BSc with Honors from City Business School, London.
ADRIAN LIDDELL
Chief Financial Officer and Chairman of the Board of Directors
Adrian Liddell has been Chairman of the Board and a Director of the Company since January 2010, and serves as the Company’s CFO. As CFO, he is responsible for the financial operation of the company, as well as regulatory and legal matters. Mr. Liddell has over 35 years of strategic, corporate, and financial advisory and company investment experience. From 2003 to 2006, Mr. Liddell was an investment advisor at Phoenix Equity Partners, a European private equity fund. From 1998 to 2003, Mr. Liddell served as a Managing Director of Mergers & Acquisitions at Donaldson Lufkin & Jenrette and Citigroup in London. From 1984 to 1998, Mr. Liddell held various positions in corporate finance and mergers & acquisitions at Lehman Brothers and Samuel Montagu & Co. in London. He is also an advisor to Fountainhead Capital Management Limited, an investment company based in Jersey, Channel Islands. Mr. Liddell qualified as a Chartered Accountant in 1984 with Arthur Young (now Ernst & Young) and holds an MA, Hons. from Christ’s College, University of Cambridge.
A seasoned leadership team leads Vycor.
The team brings deep expertise with a focus on advancing innovative solutions.
The Vycor team regularly updates investors with their company's news. Please fill out this form to receive the latest information.
Note: The company can only disclose information that is shared in the public domain through press releases, SEC filings, and other public forums. As securities law and industry regulations require, such information will always be shared with all investors simultaneously.